Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PPM1B | O75688 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5426986 | 1.00 | CHRNB2 (0.44) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL5426977 | 1.00 | CHRNB2 (0.44) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL3882191 | 0.89 | MAPK1 (0.44) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL5423546 | 0.89 | MAPK1 (0.44) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL172396 | 0.89 | MAPK1 (0.44) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL131185 | 0.89 | MAPK1 (0.44) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL14462223 | 0.89 | MAPK1 (0.44) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL5423549 | 0.89 | MAPK1 (0.44) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL3883906 | 0.89 | MAPK1 (0.44) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL14539942 | 0.88 | PPM1B (0.43) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037975-A1 | Substituted-1,3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties | BELLEAU BERNARD | 2007-02-15 | — | — | US | claimed |
| US-20040254201-A1 | Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties | BELLEAU BERNARD (CA) | 2004-12-16 | — | — | US | claimed |
| US-20030087918-A1 | Synthesis of substituted 1,3-dioxolanes and substituted 1,3-oxathiolanes with antiviral properties | BIOCHEM PHARMA INC. (CA) | 2003-05-08 | — | — | US | claimed |
| US-20070037977-A1 | Substituted-1, 3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties | BELLEAU BERNARD | 2007-02-15 | — | — | US | disclosed |
| US-20070037977-A1 | Substituted-1, 3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties | BELLEAU BERNARD | 2007-02-15 | — | — | US | disclosed |
| US-20070037975-A1 | Substituted-1,3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties | BELLEAU BERNARD | 2007-02-15 | — | — | US | disclosed |
| US-20070037975-A1 | Substituted-1,3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties | BELLEAU BERNARD | 2007-02-15 | — | — | US | disclosed |
| US-7122693-B2 | Acetaldehyde acetal compounds, their synthesis, and uses thereof | SHIRE BIOCHEM INC. (CA) | 2006-10-17 | — | — | US | disclosed |
| US-7119202-B1 | Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties | GLAXO WELLCOME INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-6903224-B2 | Substituted 1,3-oxathiolanes | BIOCHEM PHARMA INC. (CA) | 2005-06-07 | — | — | US | disclosed |
| US-20040254201-A1 | Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties | BELLEAU BERNARD (CA) | 2004-12-16 | — | — | US | disclosed |
| US-20030087918-A1 | Synthesis of substituted 1,3-dioxolanes and substituted 1,3-oxathiolanes with antiviral properties | BIOCHEM PHARMA INC. (CA) | 2003-05-08 | — | — | US | disclosed |
| US-6350753-B1 | 2-ACETOXYMETHYL-4-(THYMIN-1'-YL)-1,3,-DIOXOLANE; 2-BENZOYLOXYMETHYL-4-(CYTOSIN-1'-YL)-1,3-DIOXOLANE; ANTIVIRAL AGENTS, PARTICULARY FOR THE TREATMENT OF THE HIV INFECTIONS IN MAMMALS, ESPECIALLY HUMANS | BIOCHEM PHARMA INC. (CA) | 2002-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037977-A1 | Substituted-1, 3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties | IFNAR1, MAVS, IFNG | CHRNB2 4692/4885CHRNA5 4320/4885CHRNA7 4123/4885 |
| US-20070037975-A1 | Substituted-1,3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties | IFNAR1, MAVS, IFNG | CHRNB2 4699/4885CHRNA5 4345/4885CHRNA7 4166/4885 |
| US-20030087918-A1 | Synthesis of substituted 1,3-dioxolanes and substituted 1,3-oxathiolanes with antiviral properties | IFNAR1, ZC3HAV1, NUDT1 | CHRNB2 4678/4885CHRNA5 4378/4885CHRNA7 4035/4885 |
| US-20040254201-A1 | Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties | IFNAR1, ZC3HAV1, MAVS | CHRNB2 4555/4885CHRNA5 4167/4885CHRNA7 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.